Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Lenvatinib vs HAIC in Resectable HCC
NCT05519410Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Aug 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab and lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Disease-Free Survival at 12 months. Status: unknown.
02
Drugs
sintilimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05519410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05519410.